Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

Jitka Fucikova*, Lenka Palova-Jelinkova, Vanessa Klapp, Peter Holicek, Tereza Lanickova, Lenka Kasikova, Jana Drozenova, David Cibula, Beatriz Álvarez-Abril, Elena García-Martínez, Radek Spisek, Lorenzo Galluzzi

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Citations (Scopus)


At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.

Original languageEnglish
Pages (from-to)426-444
Number of pages19
JournalTrends in Cancer
Issue number5
Publication statusPublished - May 2022
Externally publishedYes


  • PARP inhibitors
  • antiangiogenic agents
  • bevacizumab
  • immunogenic cell death
  • platinum derivatives
  • taxanes


Dive into the research topics of 'Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents'. Together they form a unique fingerprint.

Cite this